Immun Inflamm Dis:木聚硫钠在实验性过敏性鼻炎中的光谱Th2中和作用和抗炎症作用

2017-05-21 AlexYang MedSci原创

Th2细胞激素就像白介素-4、-5和-13,被认为是过敏性鼻炎(AR)和哮喘的免疫病理学的重要驱使因子。最近,有研究人员探索了一种半合成的类肝素大分子碳水化合物-木聚硫钠(PPS)体内结合Th2细胞激素和发挥生物学中和作用以及抗炎症作用的能力。研究人员利用表面等离子共振(SPR)来检测PPS结合重组的Th2的能力,并利用Th2依赖的细胞增殖分析实验评估了生物学Th2中和作用。另外,利用鉴定过的AR

Th2细胞激素就像白介素-4、-5和-13,被认为是过敏性鼻炎(AR)和哮喘的免疫病理学的重要驱使因子。最近,有研究人员探索了一种半合成的类肝素大分子碳水化合物-木聚硫钠(PPS)体内结合Th2细胞激素和发挥生物学中和作用以及抗炎症作用的能力。研究人员利用表面等离子共振(SPR)来检测PPS结合重组的Th2的能力,并利用Th2依赖的细胞增殖分析实验评估了生物学Th2中和作用。另外,利用鉴定过的AR豚鼠模型研究体内PPS的抗炎症作用。

研究结果发现,结合研究表明了PPS对IL-4、IL-5和IL-13具有强烈的和特异的结合,并且IC值暗示了PPS可以表现出比肝素更强的细胞激素结合能力。PPS的细胞激素结合生物中和作用在抑制Th2依赖的细胞增殖中是剂量依赖型的。另外,在对敏感动物的鼻过敏原接种挑战的前30分钟进行PPS局部给药,可以显著的减少晚期血浆外渗、嗜酸细胞腔涌入、中性粒细胞和总的白细胞。相似的,尽管没有统计意义上的担保,研究还发现了对组织白血球和过度黏液分泌的影响。另外,PPS的抗炎症作用能够与局部鼻激素治疗相比。最后,研究人员指出,这项研究表明了PPS可以作为一个强有力的Th2细胞激素结合分子,并具有体内生物中和能力和广谱的抗炎症作用。PPS是AR治疗的潜在的候选分子并且PPS的临床效果急需更深入的研究。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012256, encodeId=2662201225628, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Apr 08 13:18:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057590, encodeId=ba7f205e59036, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Mon Jun 19 16:18:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046836, encodeId=55442046836dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Oct 28 16:18:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040695, encodeId=c17e204069540, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Dec 30 16:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454806, encodeId=b1b81454806d9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue May 23 12:18:00 CST 2017, time=2017-05-23, status=1, ipAttribution=)]
    2018-04-08 cmj8wellington
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012256, encodeId=2662201225628, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Apr 08 13:18:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057590, encodeId=ba7f205e59036, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Mon Jun 19 16:18:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046836, encodeId=55442046836dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Oct 28 16:18:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040695, encodeId=c17e204069540, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Dec 30 16:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454806, encodeId=b1b81454806d9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue May 23 12:18:00 CST 2017, time=2017-05-23, status=1, ipAttribution=)]
    2017-06-19 lxg951
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012256, encodeId=2662201225628, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Apr 08 13:18:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057590, encodeId=ba7f205e59036, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Mon Jun 19 16:18:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046836, encodeId=55442046836dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Oct 28 16:18:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040695, encodeId=c17e204069540, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Dec 30 16:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454806, encodeId=b1b81454806d9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue May 23 12:18:00 CST 2017, time=2017-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012256, encodeId=2662201225628, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Apr 08 13:18:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057590, encodeId=ba7f205e59036, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Mon Jun 19 16:18:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046836, encodeId=55442046836dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Oct 28 16:18:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040695, encodeId=c17e204069540, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Dec 30 16:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454806, encodeId=b1b81454806d9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue May 23 12:18:00 CST 2017, time=2017-05-23, status=1, ipAttribution=)]
    2017-12-30 lujian
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012256, encodeId=2662201225628, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Apr 08 13:18:00 CST 2018, time=2018-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057590, encodeId=ba7f205e59036, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Mon Jun 19 16:18:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046836, encodeId=55442046836dd, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Oct 28 16:18:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040695, encodeId=c17e204069540, content=<a href='/topic/show?id=5887461103d' target=_blank style='color:#2F92EE;'>#实验性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46110, encryptionId=5887461103d, topicName=实验性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sat Dec 30 16:18:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454806, encodeId=b1b81454806d9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Tue May 23 12:18:00 CST 2017, time=2017-05-23, status=1, ipAttribution=)]
    2017-05-23 xiaoyeshuang

相关资讯

Int Immunopharmacol:1,25-二羟维生素D3在卵清蛋白诱导的过敏性鼻炎模型中的效应

IL-17产生的Th17细胞在过敏性气道疾病中起着重要的作用,但是人们对它们的局部表达和在过敏性鼻炎(AR)中的调控并没有很好的理解。最近,有研究调查了1,25-二羟维生素D3(1,25-(OH)2D3)对T-bet表达、Th1 细胞, Th2 细胞, Th17 细胞 和 IL-33阳性上皮细胞在AR中影响。C57BL/6小鼠是鼻敏感型的并用卵清蛋白进行挑战接触,并且向AR小鼠中进行1,25-(O

Oncotarget:白细胞介素-17中和反应是如何抑制过敏性鼻炎症状的?

过敏性鼻炎一直以来被认为主要跟Th2细胞活动有关,而与Th1细胞的关系较少。近年来,关于Th17和调节性T细胞的发现,致使1/Th2平衡范式更为复杂,也扩大了我们对过敏性鼻炎发病机制的理解。IL-17,一个由Th17产生的关键细胞因子,被认为在哮喘中诱导过敏原特异性Th2细胞激活,嗜酸性粒细胞和嗜中性粒细胞的积累,以及血清免疫球蛋白E的产生。所有这些特征也许在过敏性鼻炎中也起到重要作用。据我们所知

Allergy Asthma Immunol Res:学龄前儿童过敏性鼻炎及呼出气一氧化氮的临床应用

学龄前儿童过敏性鼻炎(AR)的本质仍旧没有完全的鉴定。最近,有研究调查了AR的流行程度和在学龄前儿童的相关风险因子,并且还评估了呼出气一氧化氮(FeNO)的临床应用。研究方法为基于普通群体的横断式调查法,包括了来自韩国的933名学龄前儿童(3-7岁)。研究中的AR定义为在过去12个月有鼻部症状和医师诊断的AR。研究发现,目前AR在学龄前儿童的流行度为17%(156/919)。在婴儿期霉菌的接触(a

中医中药能不能治疗过敏性鼻炎

作为西医医生,常常听到很多过敏性鼻炎患者在咨询:中医中药可以治疗过敏性鼻炎吗?让我们来具体分析一下。中医理论体系中的过敏性鼻炎中医理论将过敏性鼻炎称为“鼻鼽”,并根据中医的辨证体系将其具体分为肺气虚寒型、脾气虚弱型、肾阳不足型、肺经伏热型和邪伏少阳型等症型,又根据不同症型进行具体治疗,包括内治法(中药和中成药等)和外治法(中药熏洗、塞鼻和针灸等),可谓是个体化治疗的典范。但是中医治疗该病缺乏宏观和

预防儿童过敏性鼻炎,从日常生活开始

小儿过敏性鼻炎,即小儿变应性鼻炎,是变态反应性鼻炎的简称。变应性鼻炎是儿童极为常见的一种慢性鼻黏膜充血的疾病,主要的临床症状有鼻痒、打喷嚏、流清鼻涕、鼻塞、鼻涕倒流、夜间突然咳嗽。和感冒不同的是,变应性鼻炎一般是在气候改变、早上起床,或吸入外界过敏性抗原如空气中的粉尘时发作,一天之中可能间歇出现。预防性治疗1.避免变应原和刺激物:戴口罩可以防止文中所提到的柳絮或粉尘飞入鼻孔,且避开风大柳絮多的时间

Allergol Int: 日本青少年中,HLA-DPB1与日本柳杉花粉病和致敏作用的关系

过敏性鼻炎(AR)是一种多样化的障碍疾病并且能够显著的影响日常活动、工作效率、睡眠、学习以及生活质量。日本柳杉(JC)花粉是日本最普遍的AR的过敏原。由JC花粉引起的AR被认为是一种多因子的遗传性疾病,且有环境和遗传因素共同导致的。最近,有研究人员就人类白细胞抗原-PDB1(HLA-DPB1)与JC花粉病和致敏性的关系进行了研究。研究包含了2013年到2015年的544名来自日本筑波大学的学生,并